Citigroup
PEAR

Citigroup’s Pear Therapeutics, Inc. Class A Common Stock PEAR Stock Holding History

Citigroup’s Portfolio PEAR Stock Details PEAR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-831
Closed -$981 – 6008
2022
Q4 		$981 Sell
831
-611
-42% -$1.28K ﹤0.01% 5399
2022
Q3 		$3K Sell
1,442
-4,690
-76% -$7.96K ﹤0.01% 5447
2022
Q2 		$9K Buy
6,132
+6,082
+12,164% +$23.8K ﹤0.01% 5429
2022
Q1 		$0 Buy
+50
New +$227 ﹤0.01% 6760

Other funds holding PEAR

Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
AV
Arboretum Ventures Ann Arbor, Michigan $1.72M AUM 82.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TAA
TB Alternative Assets Grand Cayman, Cayman Islands $623M AUM 154.99% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Citigroup's PEAR Position: Q1 2023 in Review

Citigroup sold out of Pear Therapeutics, Inc. Class A Common Stock (PEAR) in Q1 2023, closing a stake of 831 shares — an estimated $981 sold.

Citigroup first reported a position in PEAR in Q1 2022 and held it in 4 quarters. The position peaked at $9K in Q2 2022. 53 funds tracked by Wall St. Rank hold PEAR as of Q1 2023.

  • Citigroup reported no remaining Pear Therapeutics, Inc. Class A Common Stock position as of Q1 2023 after selling out during the quarter.
  • Citigroup sold 831 Pear Therapeutics, Inc. Class A Common Stock shares in Q1 2023, an estimated $981.
  • Citigroup first reported a position in Pear Therapeutics, Inc. Class A Common Stock in Q1 2022 and held it in 4 quarters.
  • Citigroup's Pear Therapeutics, Inc. Class A Common Stock position peaked at $9K in Q2 2022.
  • 53 funds tracked by Wall St. Rank held Pear Therapeutics, Inc. Class A Common Stock as of Q1 2023.

Based on Citigroup's 13F filing for Q1 2023, filed 11 May 2023.